the authors identified 49 gene coexpression networks, and a pathway enrichment analysis showed that "regulation of cAMPdependent protein kinase activity" was the top pathway that was negatively correlated with b-agonist use and asthma severity. Importantly, the culture model reinforced these in vivo findings.
Unbiased clustering is now commonly used to study multiple biomarkers because it allows the identification of as yet unknown associations and mechanistic networks. This follows our appreciation that stratification by clinical criteria is inadequate because a comparison of biomarker levels within groups defined by clinical severity shows very large variability within individual clinical severity strata. Using unbiased clustering of combined BAL and epithelial brushing data, Weathington and colleagues found five clusters, four of which were either highly enriched or composed entirely of subjects with asthma. Three of the clusters had typical features of type 2 (T2) asthma, and one of them was enriched for subjects with severe asthma with the longest duration and a profile that was consistent with T2-low asthma.
As the authors acknowledge, adherence was not formally assessed, which is a shared weakness of SARP and U-BIOPRED because the fractional exhaled nitric oxide suppression test, now validated for clinical application (12), was not available at the time of recruitment in both consortia. The finding of upregulated genes that have been shown by other investigators to be induced by corticosteroids does indeed suggest, as the authors state in the paper, that prescribed medication was taken, but because nothing is known about the time course of steroid-induced induction of these genes, this association cannot be taken as a guarantee of regular treatment at the time samples were taken.
This study further reinforces the view that severe asthma is now widely considered a disease composed of a number of clinically defined phenotypes and mechanism-defined endotypes (13) . As the authors propose, it offers a fertile ground for hypothesis testing. Because we know so little about non-T2 asthma, the single cluster that was characterized by low expression of T2 genes could be studied in more depth, which we should be able to do by using as metadata other biomarkers not reported in this paper. The authors caution that their finding that b-agonist exposure had the strongest impact on gene expression may not relate to disease mechanisms; however, one way or another, treatment with this class of drugs is likely to modulate a multitude of mechanisms. How and to what extent this may occur remains incompletely understood, even though we have been using these drugs for decades. The data from this study could be linked to the genetics data that the SARP consortium has acquired to see how the ADRB2 polymorphisms fit into the observed endotypes. Furthermore, links with obesity, which is also genetically associated with ADRB2 polymorphism (14) , could be explored, not least because obesity is a known risk factor for asthma and is independently correlated with oxidative stress. The same goes for the observations of corticosteroiddysregulated genes. Of note, ADRB2 gene activity is positively regulated by glucocorticoids. It is difficult to study how these two drug classes impact mechanisms, because both are central to asthma management. Therefore, other ways, including the use of mouse and cell culture models and clinical studies applying different doses of corticosteroids, need to be considered to determine how different doses influence gene expression. The challenge is to decide how best to take these findings forward. Now in its third funding period, SARP continues to show the enormous value and cost-effectiveness of large collaborative research studies to address questions in ways that could never be done by individual academic institutions or pharmaceutical companies. U-BIOPRED has been similarly productive. The findings from both consortia need to be validated, and cross-interrogation of the respective datasets would be of enormous value. We are now well into the era of asthma biologics, and a set of approved monoclonal antibodies that target different pathways is available. To understand how these drugs work on mechanisms, we need to use omics methods like the ones applied in this study. n 
Can Macrolide Antibiotics Prevent Hospital Readmissions?
Exacerbations of chronic obstructive pulmonary disease (COPD) are one of the most common causes of impaired health status and hospital admissions, as well as readmissions that are costly to healthcare services (1). The European COPD audit has shown that after an exacerbation, 35% of patients will be readmitted to the hospital within 90 days (2) . Therapy for an acute exacerbation is currently dependent on courses of oral corticosteroids and/or antibiotics, and there is no evidence that this impacts exacerbation readmissions. Other interventions are urgently required, and although some studies have investigated the use of antiinflammatory agents for acute exacerbations, including TNF-a (tumor necrosis factor-a) inhibitors (3) and phosphodiesterase E4 inhibitors (4), no effect has been shown either on exacerbation recovery or on time to the next 
